Work will be carried out at Oklahoma City facility.

ImmunoGen chose Cytovance Biologics for process development, cell banking, and cGMP manufacturing for one of its antibodies. The project will be carried out at Cytovance’s 44,000 sq. ft. cGMP production facility in Oklahoma City.

Cytovance specializes in the execution of clinical production of antibody and recombinant protein products derived from cell culture at scales of up to 500L (w/v) from both fed-batch and perfusion processes, according to the firm.

Previous articlePoint of View: Genetic Science Confounds Students
Next articleInvestigators Discover Genetic Mutation Associated with Increased Risk of Lung Cancer